
Amlodipine
3-Ethyl-5-methyl (±) - 2 - [(2 - aminoethoxy)methyl] - 4 - (2 - chlorophenyl) - 1,4 - dihydro - 6 - methyl - 3,5 - pyridinedicarboxylate, monobenzenesulphonate monohydrate
2. 本品降血壓作用的反應機轉在於對血管平滑肌的鬆弛作用,本品舒緩心絞痛的確實作用機轉不很清楚。
Absorption
Tmax is 6 to 12 h.
Distribution
Bioavailability is 64% to 90%. About 93% is protein bound.
Metabolism
About 90% is converted to inactive metabolites in the liver.
Elimination
10% of the parent compound and 60% of the metabolites are excreted in the urine. Elimination is biphasic. T½ is about 30 to 50 h.
Duration
24 h.
Special Populations
Hepatic Function Impairment
Clearance is decreased and AUC may increase about 40% to 60%. May require lower initial dose.
Elderly
Clearance is decreased and AUC may increase about 40% to 60%. May require lower initial dose.
Moderate to severe heart failure
Clearance is decreased and AUC may increase about 40% to 60%. May require lower initial dose.
May cause increased adverse cardiac reactions as a result of myocardial depression.
FentanylSevere hypotension or increased fluid volume requirements have occurred with similar drug.
2. 雖然老年人比年輕人有較高的血漿濃度,但二者之排泄半衰期相近,以類似劑量使用於老年人或年輕人,耐受性相似,因此一般劑量可推薦使用。
3. 本品大部份被代謝成非活性的代謝物,只有10%,以原型由尿液排泄,本品血漿濃度的改變和腎臟的損傷程度無關,所以在此類病人可給予正常的劑量。本品不可透析。
4. 孕婦及授乳之使用本品宜小心。
5. 本品可能造成頭暈、目眩,病人在站立或走路時應小心扶持。




